Medicare Expands Access to Wegovy for Obesity Treatment
Event summary
- Wegovy® (semaglutide) is now available to eligible Medicare beneficiaries through the Medicare GLP-1 Bridge program, effective July 1, 2026.
- The program offers Wegovy® injection and pill for a $50 monthly copay, running through the end of 2027.
- Wegovy® is the only weight management medicine proven to reduce the risk of major cardiovascular events in patients with obesity and known heart disease.
- Since its launch in January 2026, Wegovy® pill has reached 3 million prescriptions.
The big picture
The Medicare GLP-1 Bridge program addresses long-standing barriers to obesity treatment access for older Americans, a demographic with a high burden of both obesity and cardiovascular disease. This initiative aligns with broader industry trends recognizing obesity as a chronic disease requiring long-term management. Novo Nordisk's strategic move underscores its commitment to expanding affordable access to FDA-approved treatments, potentially influencing future healthcare policies and insurance coverage.
What we're watching
- Regulatory Dynamics
- Whether the Medicare GLP-1 Bridge program will serve as a catalyst for creating a permanent pathway to comprehensive obesity care within Medicare and across private insurance.
- Market Penetration
- The pace at which Wegovy® adoption will grow among Medicare beneficiaries, given the new access pathway and affordable copay structure.
- Competitive Positioning
- How Novo Nordisk will leverage this strategic move to maintain its leadership in the GLP-1 medicine category amid potential regulatory and market shifts.
Related topics